In January 2023, the American Society of Anesthesiologists (ASA) published their first-ever practice guideline for monitoring and antagonism of neuromuscular blockade. This document updates clinical standards of practice after recent advancements in both reversal medications and monitoring technology. Two pharmacological antagonists are used for the reversal of neuromuscular blockade: neostigmine and a much newer drug, sugammadex. From August 1st, 2023, through February 29, 2024, UMMC-IRB-2023-155 identified patients who required and thus received sugammadex as a reversal agent, what amount of the drug was needed to achieve >90% TOFR and the results are fascinating.
Learning Objectives:
Understand the results from UMMC-IRB-2023-155 prospective study titled "Titrating Sugammadex to Reverse Neuromuscular Blockade to >90% Train-of-Four Ratio" which was conducted from August 1, 2023-February 29, 2024.
Identify a new dosing methodology which enables tailored doses of sugammadex to be titrated to each patient's specific need.
.jpg "Blakeley F. Ward, MSN, CRNA photo")